This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Von Bibra, H. Articles by Schumm-Draeger, P.-M. Search for Related Content PubMed PubMed Citation Articles by Von Bibra, H. Articles by Schumm-Draeger, P.-M. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Diabetes Hazardous Substances DB MALONALDEHYDE METFORMIN HYDROCHLORIDE Social Bookmarking                         What's this?

Rosiglitazone, but not glimepiride, improves myocardial diastolic function in association with reduction in oxidative stress in type 2 diabetic patients without overt heart disease

Department of Endocrinology, Diabetes and Vascular Medicine, Academic Teaching Hospital Munich-Bogenhausen of the Technical University, Munich, Germany.

Michaela Diamant

Department of Endocrinology/Diabetes Center and Clinical Chemistry, VU University Medical Center, Amsterdam, The Netherlands.

Peter G Scheffer

Department of Endocrinology/Diabetes Center and Clinical Chemistry, VU University Medical Center, Amsterdam, The Netherlands.

Thorsten Siegmund

Department of Endocrinology, Diabetes and Vascular Medicine, Academic Teaching Hospital Munich-Bogenhausen of the Technical University, Munich, Germany.

Petra-Maria Schumm-Draeger

Department of Endocrinology, Diabetes and Vascular Medicine, Academic Teaching Hospital Munich-Bogenhausen of the Technical University, Munich, Germany.

The effects of thiazolidinediones on cardiac function are controversial in humans with type 2 diabetes (T2DM) and in animals. Given the high prevalence and prognostic relevance of diastolic myocardial dysfunction in T2DM, we tested the hypothesis that by reducing oxidative stress rosiglitazone, but not glimepiride, may improve diastolic function.

This randomised cross-over study investigated 12 met-formin-treated T2DM patients without cardiovascular disease before and after 16 weeks of additional therapy with rosiglitazone (8 mg daily) or glimepiride (3 mg daily). Systolic and diastolic myocardial velocity (E’) were assessed with tissue Doppler.

In spite of similar non-significant lowering of glycosylated haemoglobin (HbA1C), rosiglitazone, but not glimepiride, significantly improved E’ (p=0.04), reduced malondialdehyde (p=0.028), lowered high-sensitivity C-reactive protein (hsCRP) (p=0.019), and increased adiponectin (p=0.002). For rosiglitazone, multivariate regression analysis revealed malondialdehyde reduction as an independent determinant of treatment-induced improvement in E’.

The rosiglitazone-induced improvements of diastolic function and oxidative stress may be of prognostic relevance in choosing therapy for T2DM patients without overt heart disease.

Key Words: diastolic function • oxidative stress • rosiglitazone • thiazolidinediones • tissue Doppler • type 2 diabetes

Diabetes and Vascular Disease Research, Vol. 5, No. 4, 310-318 (2008)
DOI: 10.3132/dvdr.2008.045


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				R. W. van der Meer, L. J. Rijzewijk, H. W.A.M. de Jong, H. J. Lamb, M. Lubberink, J. A. Romijn, J. J. Bax, A. de Roos, O. Kamp, W. J. Paulus, et al. Pioglitazone Improves Cardiac Function and Alters Myocardial Substrate Metabolism Without Affecting Cardiac Triglyceride Accumulation and High-Energy Phosphate Metabolism in Patients With Well-Controlled Type 2 Diabetes Mellitus Circulation, April 21, 2009; 119(15): 2069 - 2077. [Abstract] [Full Text] [PDF]